Gelteq Ltd is a US-listed company in the pharmaceuticals industry. Its financial year ends in June.
Stock price today
Loading chart…
Third-party market data · may be delayed
Fair value per share
Under review: data-quality checks not passed.
Price vs value
Under review: data-quality checks not passed. We'll show the comparison once resolved.
Gelteq Ltd valuation: adjust assumptions and compare models →
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Funds3 adding, 4 cuttingOf 2 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Free cash flow diverging from earnings: TTM free cash flow fell 408.5% while net income fell 85.2%: a 323pp divergence.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
- Net cash. Cash exceeds long-term debt by $0.0bn.
Things to watch
- Loss-making. Operating margin is -3317.7%: costs exceed revenue.
- Burning cash. Free cash flow was -3335.3% of revenue over the last 12 months.
- Share dilution. Diluted shares rose 14.2% in a year.
Price chart
- 1 day0.0%
- 1 week+9.6%
Loading chart…
Third-party market data · may be delayed
At a glance
Profitability
- Revenue (TTM)
- $107,317
- Operating margin
- -3317.7%
- Net margin
- -4011.9%
- EPS (TTM, diluted)
- $-0.46
Growth
- Share count change
- +14.2%
Cash
- Free cash flow (TTM)
- -$3.6M
- FCF margin
- -3335.3%
News & updates
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for GELS from the sources we follow. See filings →
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Analysts' consensus
No analyst estimates are published for Gelteq Ltd: too few analysts cover it.
Positioning
- Short interest
- 4.4% of tradable shares
- Days to cover
- 0.2 at average volume
- Short interest, 1 month
- +44% to October 15, 2026
- Held by institutions
- 1% of shares
- Held by insiders
- 47.5% of shares
- Employees
- 7 full time
Share-price performance
Market data may be delayedPrice behaviour
- 52-week range
- Not enough history
- From 52-week high
- —
- vs 50-day average
- —
- vs 200-day average
- —
- Volatility (1 year)
- —
- Beta vs S&P 500
- —
Fundamentals
Financial statements
| Fiscal year | 2023 Jun 2023 | 2025 Jun 2025 |
|---|---|---|
| Income | ||
| Revenue | 54 | 107 |
| Gross profit | — | 33 |
| EBITDA | −1,263 | −2,768 |
| Operating income | −2,088 | −3,560 |
| Net income | −2,360 | −4,305 |
| Diluted EPS | −$0.30 | −$0.47 |
| Growth (year on year) | ||
| Revenue | — | +99.7% |
| Margins | ||
| Gross margin | — | 30.3% |
| EBITDA margin | <−999% | <−999% |
| Operating margin | <−999% | <−999% |
| Net margin | <−999% | <−999% |
| Free-cash-flow margin | <−999% | <−999% |
| Cash flow | ||
| Cash from operations | −1,192 | −3,577 |
| Capital spending | 23 | 2 |
| Free cash flow | −1,215 | −3,579 |
| Balance sheet | ||
| Cash | 266 | 227 |
| Total debt | 1,650 | 2,772 |
| Net debt (negative = net cash) | 1,384 | 2,546 |
| Diluted shares | 8m | 9m |
Financial health
- Short-term assets cover short-term liabilities $990,334 of assets due within a year against $4m of liabilities due within a year.
- Short-term assets cover long-term liabilities $990,334 short-term assets against $25,334 of longer-dated liabilities.
- More cash than debt $226,537 of cash against $3m of debt.
- Debt below 40% of shareholders' equity Debt is 27% of equity.
- Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
- A year's operating cash flow covers at least 20% of debt −$4m of operating cash flow against $3m of debt.
- Operating profit covers interest at least five times over Operating income of −$4m against $1m of interest.
Dividends, buybacks and capital spending
- Diluted share count
- +14.2%
- year over year
- R&D spending
- 379.5%
- of revenue
- Days sales outstanding
- 1028 days
- receivables vs revenue
Competitors: side by side with peers
| Last 12 months unless stated | GELS | AKAN | PRFX | SCNX | SXTP | SXTC | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $107317 | $258075 | $17000 | $821315 | $1m | $1m | $254m |
| Revenue growth, last 12 months | — | −69.2% | — | 540.6% | 73.2% | −34.6% | 9.9% |
| Revenue growth, 3-year average | — | — | — | −58.5% | 74.9% | — | 5.5% |
| Revenue growth, latest quarter | — | — | — | 449.1% | 106.0% | — | 6.5% |
| Gross margin | 30.3% | −60.5% | −311.8% | 87.7% | 19.4% | 21.9% | 60.1% |
| Operating margin | <−999% | <−999% | <−999% | <−999% | −774.9% | −625.9% | −5.9% |
| Operating margin, 3-year average | — | — | — | <−999% | <−999% | −267.4% | −7.4% |
| Net margin | <−999% | −467.1% | <−999% | <−999% | −729.9% | −545.2% | −7.4% |
| Cash from operations / revenue | <−999% | <−999% | <−999% | <−999% | −789.8% | −353.0% | 9.4% |
| Free-cash-flow margin | <−999% | <−999% | <−999% | <−999% | −800.6% | −353.0% | 8.1% |
| Free-cash-flow margin, 3-year average | — | — | — | <−999% | — | −126.6% | 7.4% |
| Stock pay / revenue | — | 21.3% | >999% | 257.1% | 37.2% | 466.2% | 3.6% |
| Change in share count | 14.2% | −93.4% | 368.7% | 2.1% | — | >999% | 2.0% |
Who owns it
Funds buying and selling- Reported value
- $73,286
- Institutions reporting
- 6
- Shares held vs prior quarter
- ▲ 76.3%
- Positions opened / closed
- 3 / 2
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Two Sigma Securities, LLC | $22,269 | 33K | 30.4% | New |
| Jane Street Group, LLC | $20,208 | 30K | 27.6% | New |
| Wedbush Securities Inc | $13,000 | 20K | 17.7% | 0.0% |
| Morgan Stanley | $10,050 | 15K | 13.7% | New |
| Citadel Advisors LLC | $7,676 | 11K | 10.5% | ▼ 17.2% |
| UBS Group AG | $83 | 0K | 0.1% | ▼ 93.2% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Gelteq Ltd's complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chartFrom insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Gelteq Ltd in brief
- What does Gelteq Ltd do?
- Gelteq Ltd is a US-listed company in the pharmaceuticals industry. Its financial year ends in June.
- What is Gelteq Ltd's stock ticker?
- Gelteq Ltd trades under the ticker GELS on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- What is Gelteq Ltd's free cash flow?
- Gelteq Ltd's free-cash-flow margin is -3335.3% of revenue over the trailing twelve months.
- Who are Gelteq Ltd's largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Two Sigma Securities, LLC, Jane Street Group, LLC and Wedbush Securities Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- How much debt does Gelteq Ltd have?
- Gelteq Ltd's debt-to-equity ratio is 26.7%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
- Who are Gelteq Ltd's competitors?
- In our Pharmaceuticals peer group, the companies closest to Gelteq Ltd are Akanda Corp., PRF Technologies Ltd., Scienture Holdings, Inc., 60 Degrees Pharmaceuticals, Inc. and China SXT Pharmaceuticals, Inc. The side-by-side comparison below sets their revenue, margins and growth against Gelteq Ltd's.
Follow research on Gelteq Ltd
New research on the companies we cover arrives in the weekly email. Free, one email a week.